shRNA and siRNA delivery to the brain (scientific article published on 16 March 2007)

Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate

Q34058435

Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo

Q34239620

EGFR and cancer prognosis

Q34399312

The effects of polycations on vascular permeability in the rat. A proposed role for charge sites

Q34607667

Neuroprotection with noninvasive neurotrophin delivery to the brain

Q34802946

Gene silencing in mammals by small interfering RNAs

Q34931992

Noninvasive gene targeting to the brain

Q35163431

Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system

Q38287477

Non–Sequence-Specific Inhibition of Transferrin Receptor Expression in HL-60 Leukemia Cells by Phosphorothioate Oligodeoxynucleotides

Q38337527

Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages

Q40389198

Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology.

Q40506666

Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer

Q40550050

Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

Q40834751

Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor

Q40881449

An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain.

Q41694333

Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier.

Q41712976

Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse.

Q41721402

Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups

Q41760845

Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system

Q43626844

Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes

Q43653658

In vitro stability of alpha-helical peptide nucleic acids (alphaPNAs).

Q43723268

Receptor-mediated delivery of an antisense gene to human brain cancer cells

Q43947685

Rapid transferrin efflux from brain to blood across the blood-brain barrier

Q44085165

Widespread expression of an exogenous gene in the eye after intravenous administration.

Q44119141

RNAi in human cells: basic structural and functional features of small interfering RNA.

Q44199577

Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.

Q44305889

Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer

Q44613306

Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector

Q44661842

Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter

Q44821882

Antisense gene therapy of brain cancer with an artificial virus gene delivery system

Q45731908

Stabilization of poly-L-lysine/DNA polyplexes for in vivo gene delivery to the liver

Q45856362

Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation

Q45870694

Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes

Q45880218

Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.

Q46032203

Gene targeting in vivo with pegylated immunoliposomes

Q46173833

Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor

Q46454399

In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats

Q48122926

PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli

Q48319236

Global non-viral gene transfer to the primate brain following intravenous administration

Q48393623

Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation

Q48494993

Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo

Q48643049

Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system.

Q48909700

Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin

Q49047711

Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice

Q57677348

Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo

Q69752125

Electron microscopic visualization of insulin translocation into the cytoplasm and nuclei of intact H35 hepatoma cells using covalently linked Nanogold-insulin

Q72332030

Insulin receptors in human ocular tissues. Immunohistochemical demonstration in normal and diabetic eyes

Q73619625

Free cationic liposomes inhibit the inflammatory response to cationic lipid-DNA complex injected intravenously and enhance its transfection efficiency

Q78944400

P433

issue

2-3

P407

language of work or name

English

Q1860

P304

page(s)

141-152

P577

publication date

2007-03-16

P1433

published in

Advanced Drug Delivery Reviews

Q2825362

P1476

title

shRNA and siRNA delivery to the brain

P478

volume

Reverse relations

cites work (P2860)

Q90230646	Activation of cyclin D1 affects mitochondrial mass following traumatic brain injury
Q30488727	An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells
Q37851969	Antibody-targeted nanoparticles for cancer therapy
Q46710298	Cellular uptake of fluorescent labelled biotin-streptavidin microspheres
Q60467863	Chitosan and its derivatives as nanocarriers for siRNA delivery
Q36345289	Click synthesis of a polyamidoamine dendrimer-based camptothecin prodrug.
Q37217876	Concepts in in vivo siRNA delivery for cancer therapy
Q38160246	Delivery of RNAi therapeutics: work in progress
Q34293708	Delivery of siRNA therapeutics: barriers and carriers
Q37481282	Delivery of small-interfering RNA (siRNA) to the brain
Q40286912	Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
Q42646979	Diagnosing and Treating Nervous System Disorders by Targeting Novel Classes of Non-coding RNAs
Q37425213	Differential receptor-mediated drug targeting to the diseased brain
Q37590479	Electro-Magnetic Nano-Particle Bound Beclin1 siRNA Crosses the Blood-Brain Barrier to Attenuate the Inflammatory Effects of HIV-1 Infection in Vitro
Q48164145	Elevated plasma CaM expression in patients with acute cerebral infarction predicts poor outcomes and is inversely associated with miR-26b expression
Q35090897	Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing
Q33732849	Genetic approach for intracerebroventricular delivery
Q39437235	Glioma growth inhibition in vitro and in vivo by single chain variable fragments of the transferrin receptor conjugated to survivin small interfering RNA.
Q35093276	Gold nanorod--siRNA induces efficient in vivo gene silencing in the rat hippocampus
Q38042256	Immunoconjugates and long circulating systems: origins, current state of the art and future directions
Q54957884	Improved method for synthesis of low molecular weight protamine-siRNA conjugate.
Q35846848	Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels
Q33687594	Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation
Q40070009	Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology
Q89482934	Intravenously Administered Novel Liposomes, DCL64, Deliver Oligonucleotides to Cerebellar Purkinje Cells
Q37342330	Knockdown of tyrosine hydroxylase in the nucleus of the solitary tract reduces elevated blood pressure during chronic intermittent hypoxia
Q38756973	Lentivirus mediated RNA interference of EMMPRIN (CD147) gene inhibits the proliferation, matrigel invasion and tumor formation of breast cancer cells
Q39964739	Manipulation of PKC isozymes by RNA interference and inducible expression of PKC constructs
Q27002604	MicroRNA Regulation of Brain Tumour Initiating Cells in Central Nervous System Tumours
Q33346479	MicroRNAs: regulators of oncogenesis and stemness
Q43038942	Molecular medicine: entry granted
Q21223671	Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging
Q37948968	Nanocarrier possibilities for functional targeting of bioactive peptides and proteins: state-of-the-art
Q37800505	Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System
Q33420721	Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons
Q44066855	Neuroprotective effects of microRNA-210 on hypoxic-ischemic encephalopathy
Q37024768	Nonviral delivery of synthetic siRNAs in vivo
Q37360226	Nonviral methods for siRNA delivery
Q38091009	Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?
Q37981217	Nucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression
Q42225268	Optimization and apoptosis induction by RNAi with UTMD technology in vitro
Q46021217	Physicochemical properties of a zinc phthalocyanine - pyrene conjugate adsorbed onto single walled carbon nanotubes.
Q37780603	Potential use of RNA interference in cancer therapy
Q33574535	REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy
Q47338076	RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA.
Q89638520	SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer
Q35848195	Single reporter for targeted multimodal in vivo imaging
Q37593705	Site-specific antibody drug conjugates for cancer therapy
Q37598928	Strategies for short hairpin RNA delivery in cancer gene therapy
Q37619111	Strategies for targeted nonviral delivery of siRNAs in vivo
Q38090672	Strategies to assess blood-brain barrier penetration
Q39427146	Substance P derivatives as versatile tools for specific delivery of various types of biomolecular cargo
Q92354290	Synthesis and characterization of nanometer-sized liposomes for encapsulation and microRNA transfer to breast cancer cells
Q47152520	Targeted Delivery of siRNA Therapeutics to Malignant Tumors.
Q41312221	Targeted delivery of siRNA to macrophages for anti-inflammatory treatment
Q41790608	Targeting individual calpain isoforms for neuroprotection
Q48238485	Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB).
Q26858788	The involvement of microRNAs in neurodegenerative diseases
Q24657247	The promises and pitfalls of RNA-interference-based therapeutics
Q38268541	Therapeutic face of RNAi: in vivo challenges
Q44696669	Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications
Q37270325	Vessel microport technique for applications in cerebrovascular research
Q36905867	microRNAs: innovative targets for cerebral ischemia and stroke.